Anti-autistic and anti-psychotic activity of pimozide in chronic schizophrenic patients undergoing acute exacerbations

C. S. Stier, A. Elizur, A. Yeret, S. Davidson

Research output: Contribution to journalArticlepeer-review

Abstract

An uncontrolled trial was carried out on 14 chronic schizophrenic patients with acute exacerbations in order to evaluate the therapeutic specificity of the drug pimozide in combating the target-symptoms of autism, apathy, emotional withdrawal, depression, delusions and hallucinations. Weekly evaluations were made by two psychiatrists independently during the trial period of 10 wks. During the first week, a placebo alone was administered. In the second week, an increasing dosage of pimozide was given orally up to a maximum of 16 mg/day. From the third to the tenth week, the patient received an optimal dose. In six out of 12 patients who finished the trial, marked improvement appeared in the second week and they were fit to be discharged from hospital at the end of the trial period and return to social and occupational functioning. The main symptoms that showed improvement were: depression, and somatic concern. Four patients failed to respond to the treatment. No ataractic effects were evident and in fact in two patients the drug aggravated or even precipitated psychomotor agitation, anxiety, and tension.

Original languageEnglish
Pages (from-to)632-641
Number of pages10
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume23
Issue number5 II
StatePublished - 1978

Fingerprint

Dive into the research topics of 'Anti-autistic and anti-psychotic activity of pimozide in chronic schizophrenic patients undergoing acute exacerbations'. Together they form a unique fingerprint.

Cite this